Sun Pharmaceutical Industries Limited (SUNPHARMA) Financial Results — Revenue ₹49,868.1 Cr

StockFin.ai Try Free →

Revenue: ₹49,868.1 CrNet Profit: ₹6,087 Cr

📢 Key Event
Sun Pharma announces FY26 audited financial results with ₹350,128 million revenue and ₹118,093 million net profit

🔄 What Changed
Net profit grew 26.2% YoY to ₹118,093 million; revenue increased 13.6% YoY in Q4FY26; exceptional charges of ₹17,112 million recorded

🔮 What's Next
Adopted concessional tax regime under Section 115BAA at 25.168% effective FY 2026-27

💡 Investor Takeaway
Strong profitability growth driven by tax benefits and operational performance supports dividend sustainability

Sun Pharmaceutical Industries Limited reported audited standalone financial results for FY26 ending March 31, 2026, with total revenue of ₹350,128 million and net profit of ₹118,093 million, reflecting a 13.6% YoY sales increase in Q4FY26 and 26.2% net profit growth. The company recommended a final dividend of ₹5 per share and disclosed exceptional charges of ₹17,112 million related to litigation settlements. Tax benefits from new labor code provisions and adoption of the concessional tax regime under Section 115BAA contributed to profitability. Total assets stood at ₹309,000 million, with cash and cash equivalents at ₹65,032 million. The auditor issued an unmodified opinion on consolidated financial statements.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Sun Pharmaceutical Industries Limited (SUNPHARMA) — Financial Results Announcement

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Recent Announcements from Sun Pharmaceutical Industries Limited